Literature DB >> 23672930

The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer.

Gretchen Glaser1, Michelle Torres, Bohyun Kim, Giovanni Aletti, Amy Weaver, Andrea Mariani, Lynn Hartmann, William Cliby.   

Abstract

BACKGROUND: High tumor dissemination (HTD) is a major risk factor for serious morbidity after primary ovarian cancer (OC) surgery, particularly in medically compromised patients. We performed a pilot study of whether CT findings could predict extent of disease and surgical complexity necessary in advanced OC.
METHODS: Preoperative CT images for patients with advanced OC from 1997-2003 were evaluated for rigorously defined disease-related findings and compared to both the findings at exploration and the required surgical procedures. Associations were assessed by the chi-square test.
RESULTS: Forty-six cases met inclusion criteria. Mean age was 66.4y, and 76% had residual disease (RD) 1cm or less. CT and surgical findings correlated (sensitivity/specificity) as follows: diaphragm disease (48%/100%); surface liver (100%/93%); omental cake (72%/65%); any sigmoid involvement (54%/100%); ascites (44%/100%); extra-pelvic large bowel involvement (29%/91%). When diaphragm disease and omental cake were present, HTD was found in all cases (positive predictive value and specificity=100%, sensitivity 48%). For CT findings of liver, large bowel and spleen involvement there was a strong trend toward resection (P=0.001, P=0.06 and P=0.06, respectively).
CONCLUSIONS: The findings of diaphragm disease and omental cake on CT scan are highly predictive for high tumor dissemination (HTD) and thus likelihood of extensive surgery required to achieve low residual disease. In addition, multiple CT findings correlate strongly with the need for higher surgical complexity which should facilitate preoperative planning and/or triage to specialized centers. These preliminary data suggest specific CT findings can be used to optimize treatment planning.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytoreduction; Outcome assessment; Ovarian neoplasms; Radiologic imaging

Mesh:

Year:  2013        PMID: 23672930      PMCID: PMC3753038          DOI: 10.1016/j.ygyno.2013.05.007

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  26 in total

1.  Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.

Authors:  Cornelis G Gerestein; Marinus J Eijkemans; Jeanette Bakker; Otto E Elgersma; Maria E L van der Burg; Geertruida S Kooi; Curt W Burger
Journal:  Anticancer Res       Date:  2011-11       Impact factor: 2.480

Review 2.  Optimal primary surgical treatment for advanced epithelial ovarian cancer.

Authors:  Ahmed Elattar; Andrew Bryant; Brett A Winter-Roach; Mohamed Hatem; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2011-08-10

3.  Usefulness of computed tomography in predicting cytoreductive surgical outcomes for ovarian cancer.

Authors:  Kazuko Fujwara; Kiyoshi Yoshino; Takayuki Enomoto; Masami Fujita; Yutaka Ueda; Takashi Miyatake; Toshihiro Kimura; Miho Muraji; Haruyasu Fujita; Tadashi Kimura; Masatoshi Hori
Journal:  Arch Gynecol Obstet       Date:  2011-02-24       Impact factor: 2.344

4.  The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.

Authors:  D S Chi; E S Venkatraman; V Masson; W J Hoskins
Journal:  Gynecol Oncol       Date:  2000-05       Impact factor: 5.482

5.  A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography.

Authors:  R E Bristow; L R Duska; N C Lambrou; E K Fishman; M J O'Neill; E L Trimble; F J Montz
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

6.  Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer.

Authors:  Signe Risum; Annika Loft; Claus Høgdall; Anne K Berthelsen; Estrid Høgdall; Lene Lundvall; Lotte Nedergaard; Svend A Engelholm
Journal:  Acta Oncol       Date:  2010-08-11       Impact factor: 4.089

7.  Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.

Authors:  Giovanni D Aletti; Sean C Dowdy; Karl C Podratz; William A Cliby
Journal:  Am J Obstet Gynecol       Date:  2007-12       Impact factor: 8.661

8.  Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer.

Authors:  John P Geisler; Georgiann C Linnemeier; Amanda J Thomas; Kelly J Manahan
Journal:  Gynecol Oncol       Date:  2007-04-26       Impact factor: 5.482

9.  CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.

Authors:  S Memarzadeh; S B Lee; J S Berek; R Farias-Eisner
Journal:  Int J Gynecol Cancer       Date:  2003 Mar-Apr       Impact factor: 3.437

10.  A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model.

Authors:  Giovanni D Aletti; Antonio Santillan; Eric L Eisenhauer; Jae Hu; Giacomo Aletti; Karl C Podratz; Robert E Bristow; Dennis S Chi; William A Cliby
Journal:  Gynecol Oncol       Date:  2007-06-28       Impact factor: 5.482

View more
  5 in total

1.  Risk stratification and outcomes of women undergoing surgery for ovarian cancer.

Authors:  Sonali Patankar; William M Burke; June Y Hou; Ana I Tergas; Yongmei Huang; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2015-05-11       Impact factor: 5.482

2.  An Orthotopic Murine Model of Peritoneal Carcinomatosis of Ovarian Origin for Intraoperative PDT.

Authors:  Thierry Michy; Claire Bernard; Jean-Luc Coll; Véronique Josserand
Journal:  Methods Mol Biol       Date:  2022

3.  Computed tomographic enterography (CTE) in evaluating bowel involvement in patients with ovarian cancer.

Authors:  Xiao-Mei Zhang; Xin-Yu Zhang; Yue-Xi Liu; Ruo-Nan Li; Yong-Mei Li; Hua Linghu
Journal:  Abdom Radiol (NY)       Date:  2022-04-05

Review 4.  Molecular Imaging of Ovarian Cancer.

Authors:  Sai Kiran Sharma; Brandon Nemieboka; Evis Sala; Jason S Lewis; Brian M Zeglis
Journal:  J Nucl Med       Date:  2016-04-28       Impact factor: 10.057

5.  Verteporfin-Loaded Lipid Nanoparticles Improve Ovarian Cancer Photodynamic Therapy In Vitro and In Vivo.

Authors:  Thierry Michy; Thibault Massias; Claire Bernard; Laetitia Vanwonterghem; Maxime Henry; Mélanie Guidetti; Guy Royal; Jean-Luc Coll; Isabelle Texier; Véronique Josserand; And Amandine Hurbin
Journal:  Cancers (Basel)       Date:  2019-11-08       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.